在室温下运输。储存在-20℃。 Shipped at room temperature. Store at -20°C. R-7050 is a TNF-α receptor signaling antagonist. TNF-α induces biological activity throgh stimulation of the tumor necrosis factor receptor. Although plenty of pre-clinical and clinical evidence suggests a detrimental role, small molecule TNF-αsignaling pathway inhibitors remain largely unexplored in the context of a brain hemorrhage. In vitro: R-7050 was identified as a selective inhibitot of TNF-α induced cellular signaling by using differential library screening. Unlike biologic TNF inhibitors directly binding TNF-α, R-7050 could not affect binding of TNF-α to TNFR. In contrast, R-7050 was able to selectively inhibit the association of TNF receptor with intracellular adaptor molecules In vivo: In previous animal study, R-7050 was tested to attenuate neurovascular injury after Intracerebral hemorrhage (ICH) in mice. Results showed that up to 2h post-injury administration of R-7050 was able to significantly reduce blood-brain barrier opening and attenuate edema development at 24h post-ICH. In addition, neurological outcomes were also improved over the first 3 days after injury. Whereas, R-7050 was not found to be albe to reduce hematoma volume, indicating the beneficial effects of TNFR inhibition were downstream of clot formation/resolution . Clinical trial: Up to now, R-7050 is still in the preclinical development stage.